High-dose melphalan plus bortezomib for multiple myeloma patients as a conditioning of auto-PBSCT.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2014
At a glance
- Drugs Bortezomib (Primary) ; Melphalan (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 12 May 2011 New trial record